Gilles Defer1, Sophie Fedrizzi2, Damien Chevanne1, François Montastruc3,4, Anais R Briant5, Jean-Jacques Parienti5,6, Laure Peyro-Saint-Paul7. 1. Neurology Department, Caen University Hospital, Caen, France. 2. Pharmacology Department, Caen University Hospital, Caen, France. 3. Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Toulouse University Hospital, Faculty of Medicine, University of Toulouse, Toulouse, France. 4. UMR 1027 Pharmacoepidemiology, Assessment of Drug Utilization and Drug Safety, INSERM, University Paul Sabatier Toulouse III Joint Research Unit, Toulouse, France. 5. Clinical Research Department, Caen University Hospital, 14033, Caen Cedex 9, France. 6. EA2656 Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), University of Caen Normandy, Caen, France. 7. Clinical Research Department, Caen University Hospital, 14033, Caen Cedex 9, France. peyrosaintpaul-l@chu-caen.fr.
Abstract
INTRODUCTION: Patient reporting adds value to pharmacovigilance. Encouraging it to be done through a mobile device application (App) is a method that should be evaluated. OBJECTIVE: This study aimed to determine whether the use of an App, compared to traditional use through e-mail, telephone, or the national website, increased suspected adverse drug reaction (ADR) reporting by persons with multiple sclerosis receiving a first-line disease-modifying drug. METHODS: An open multi-centric, cluster-randomized controlled trial was conducted (VigipSEP study). Clusters were centers allocated (1:1) to the use of the My eReport France® App (experimental arm), and traditional reporting (control arm). Persons with multiple sclerosis initiating or switching to a first-line disease-modifying drug between April 2017 and April 2019 were included. The primary outcome was the mean number of ADR reports per patient for the center-level analysis, and the number of ADR reports per patient for the individual-level analysis using the hierarchical Poisson regression model. RESULTS: Twenty-four centers (12 per arm: six public neurologists from the multiple sclerosis academic expert centers, three public neurologists from general hospitals, and three private practice neurologists) were randomized, including 159 patients. The mean number of ADR reports per patient was significantly higher in centers that used the App: 0.47 vs 0.03 in control centers (p = 0.002). At an individual-level analysis, the experimental arm was significantly associated with a relative risk of ADR reports at 18.6 (95% confidence interval 4.1-84.2; p < 0.001), compared to the control arm, adjusted for sex and type of disease-modifying drug. CONCLUSIONS: The use of a mobile App increased the ADR reporting by persons with multiple sclerosis receiving a first-line disease-modifying drug. CLINICALTRIALS. GOV IDENTIFIER: NCT03029897, registered in 2017.
INTRODUCTION: Patient reporting adds value to pharmacovigilance. Encouraging it to be done through a mobile device application (App) is a method that should be evaluated. OBJECTIVE: This study aimed to determine whether the use of an App, compared to traditional use through e-mail, telephone, or the national website, increased suspected adverse drug reaction (ADR) reporting by persons with multiple sclerosis receiving a first-line disease-modifying drug. METHODS: An open multi-centric, cluster-randomized controlled trial was conducted (VigipSEP study). Clusters were centers allocated (1:1) to the use of the My eReport France® App (experimental arm), and traditional reporting (control arm). Persons with multiple sclerosis initiating or switching to a first-line disease-modifying drug between April 2017 and April 2019 were included. The primary outcome was the mean number of ADR reports per patient for the center-level analysis, and the number of ADR reports per patient for the individual-level analysis using the hierarchical Poisson regression model. RESULTS: Twenty-four centers (12 per arm: six public neurologists from the multiple sclerosis academic expert centers, three public neurologists from general hospitals, and three private practice neurologists) were randomized, including 159 patients. The mean number of ADR reports per patient was significantly higher in centers that used the App: 0.47 vs 0.03 in control centers (p = 0.002). At an individual-level analysis, the experimental arm was significantly associated with a relative risk of ADR reports at 18.6 (95% confidence interval 4.1-84.2; p < 0.001), compared to the control arm, adjusted for sex and type of disease-modifying drug. CONCLUSIONS: The use of a mobile App increased the ADR reporting by persons with multiple sclerosis receiving a first-line disease-modifying drug. CLINICALTRIALS. GOV IDENTIFIER: NCT03029897, registered in 2017.
Authors: Ronald Kiguba; Helen Byomire Ndagije; Victoria Nambasa; Cordelia Katureebe; Henry Zakumumpa; Stella Maris Nanyonga; Jacquellyn Nambi Ssanyu; Phil Tregunno; Kendal Harrison; Corinne S Merle; Marie-Eve Raguenaud; Freddy Eric Kitutu Journal: BMJ Open Date: 2022-05-19 Impact factor: 3.006